SNP Analysis Method for Rheumatoid Arthritis MTX Efficacy
Solution Overview
Problem
Current methods struggle to precisely determine the efficacy of methotrexate (MTX) in patients with rheumatoid arthritis, as individual responses vary significantly, and existing genetic markers do not provide reliable predictions for therapeutic effectiveness.
Innovation Solution
A method involving the analysis of specific single nucleotide polymorphisms (SNPs) in genes such as FPGS, GGH, SLC19A1, FMO2, SLC28A3, EPHX1, and PPARG, using a computer program to calculate a numerical index and compare it against a threshold to assess MTX efficacy, with additional SNPs in GGH and SLC19A1 genes for further analysis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If a limited number of SNPs in FPGS, GGH, and SLC19A1 genes are analyzed, then the determination process is simple, but the precision of MTX efficacy prediction is insufficient
Solution Approach 1:
The patent segments the SNP analysis into two distinct groups: a first group of SNPs in FPGS, GGH, and SLC19A1 genes for initial determination, and a second group of SNPs in FMO2, SLC28A3, EPHX1, and PPARG genes for refinement when the first determination is inconclusive. This segmentation allows the system to maintain simplicity for clear cases while providing enhanced precision for ambiguous cases without always requiring full complexity.
Solution Approach 2:
The patent implements a dynamic, multi-stage determination process that adapts its complexity based on the initial results. When the first SNP analysis provides a clear determination, the process terminates early. When results are inconclusive, the system dynamically extends to include additional SNP analysis from the second group of genes, thereby adjusting the analytical depth according to the specific case requirements.
2Reliability
If multiple SNPs across multiple genes are analyzed, then the prediction precision is improved, but the determination process becomes more complex
Solution Approach 1:
The patent divides the comprehensive SNP analysis into two sequential stages with clearly defined purposes. The first stage analyzes SNPs in FPGS, GGH, and SLC19A1 genes to provide an initial determination. The second stage, activated only when needed, analyzes additional SNPs in FMO2, SLC28A3, EPHX1, and PPARG genes to resolve inconclusive cases. This segmentation maintains operational simplicity for routine cases while ensuring high reliability for challenging cases.
Solution Approach 2:
The patent applies partial action by performing only the necessary level of analysis for each case. For most cases, analyzing the first group of SNPs provides sufficient reliability, avoiding the unnecessary complexity of analyzing all SNPs. The extended analysis of the second gene group is performed only when the first analysis yields inconclusive results, thereby optimizing the balance between reliability and ease of operation.
3Measurement precision
If only FPGS, GGH, and SLC19A1 gene SNPs are analyzed, then the analysis is straightforward, but the determination accuracy is insufficient for some patients
Solution Approach 1:
The patent segments the gene analysis into a core set (FPGS, GGH, SLC19A1) for routine determination and an extended set (FMO2, SLC28A3, EPHX1, PPARG) for cases requiring higher precision. This segmentation allows the system to maintain straightforward analysis for the majority of patients while providing access to more comprehensive genetic markers when clinical circumstances warrant enhanced accuracy.
Solution Approach 2:
The patent implements a dynamic analysis strategy that adapts the scope of gene analysis based on the clinical context and initial results. The system begins with the simpler core gene analysis and dynamically extends to the more comprehensive extended gene set when the initial determination is inconclusive or when clinical judgment suggests the need for higher precision, thereby balancing analytical simplicity with determination accuracy.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Disclosed is a method for assisting diagnosis of efficacy of methotrexate (MTX) in a patient with rheumatoid arthritis, the method including the steps of: analyzing at least one of single nucleotide polymorphisms (SNPs) of at least one gene selected from FPGS gene, GGH gene, and SLC19A1 gene, at least one of SNPs of FMO2 gene, at least one of SNPs of SLC28A3 gene, at least one of SNPs of EPHX1 gene, and at least one of SNPs of PPARG gene in a biological sample obtained from a patient with rheumatoid arthritis; and determining the efficacy of methotrexate in the patient based on the analysis results.